Share-based Payment Arrangement, Expense of Vivos Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vivos Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Vivos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $100,000, unchanged year-over-year.
  • Vivos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $500,000, a 50% decline year-over-year.
  • Vivos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $800,000, a 27% decline from 2023.
  • Vivos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,100,000, a 57% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vivos Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $500,000 $100,000 $0 0% 01 Jul 2025 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $500,000 $300,000 -$300,000 -50% 01 Apr 2025 30 Jun 2025 10-Q 19 Aug 2025 2025 Q2
Q1 2025 $800,000 $300,000 $0 0% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $800,000 $200,000 -$200,000 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $1,000,000 $100,000 -$100,000 -50% 01 Jul 2024 30 Sep 2024 10-Q 19 Nov 2025 2025 Q3
Q2 2024 $1,100,000 $600,000 +$200,000 +50% 01 Apr 2024 30 Jun 2024 10-Q 19 Aug 2025 2025 Q2
Q1 2024 $900,000 $300,000 -$200,000 -40% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,100,000 $0 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $200,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $400,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $500,000 +$300,000 +150% 01 Jan 2023 31 Mar 2023 10-Q 08 Jun 2023 2023 Q1
Q1 2022 $200,000 01 Jan 2022 31 Mar 2022 10-Q/A 25 Nov 2022 2022 Q1

Vivos Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $800,000 -$300,000 -27% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $1,100,000 +$400,000 +57% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $700,000 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.